"Lp(a) and ApoCIII are potent, genetically validated cardiovascular risk reduction targets," added Vasant Narasimhan, global head of drug development, and CMO at Novartis. "Novartis is building a robust cardiovascular portfolio of targeted therapies to address unmet medical need of high-risk patients. The importance of predictive biomarkers in achieving successful cardiovascular outcomes will also be essential in the future payer environment."